ORIC Pharmaceuticals, Inc. develops therapies aimed at overcoming resistance in cancer treatment. The company focuses on enhancing the effectiveness of existing cancer therapies and advancing new treatments through clinical trials. ORIC operates in the biopharmaceutical sector, primarily serving patients with cancer. Its research and development efforts are concentrated on various oncology therapeutics, with a commitment to addressing both innate and acquired resistance to cancer treatments.
